US Business: Improvement in US business (up 25% yoy & 10% qoq) is driven by multiple factors such as: strong gain in market share in gCrestor, ramp-up in recently launched products, gMupirocin sales improvement, strong traction in derma (new launches: T-Cream, gDiclofenac, gLidocaine) and other products. Management believes that the price erosion in base business stood at 10% on account of increased approvals by the US FDA. It further expects most future launches (till FY19E) would be from derma segment, as it believes that post FY19E, the Company will see more launches in complex generic space (injectables)....